为探索gemcitabine和顺铂(DDP)联合化疗在晚期、未 控、复发的宫颈鳞癌患者的疗效及毒性,对1997年7月～1999年1月间19例从未曾接受过化疗的患者进行临床Ⅱ期研究。患者均经病理学证实为宫颈鳞癌,按GOG评分为0～2级,粒细胞计数≥1.5×10~9/L,血小板计数≥100×10~9/L,肌酐不超过1.8 mg％,胆红素不超过正常的1.5倍,肝功能不超过正常的3倍,有骨转移者具有可测量的肿瘤,即肿 To investigate the efficacy and toxicity of gemcitabine combined with cisplatin (DDP) in patients with advanced, uncontrolled and recurrent cervical squamous cell carcinoma, 19 patients who had never received chemotherapy before and between January 1997 and January 1999 were enrolled in this study Phase Ⅱ study. Patients were confirmed by histopathology as squamous cell carcinoma of the cervix. The GOG scores ranged from 0 to 2, the number of granulocyte≥1.5 × 10 ~ 9 / L, the platelet count≥100 × 10 ~ 9 / L, creatinine less than 1.8 mg% Bilirubin no more than 1.5 times the normal, liver function does not exceed 3 times the normal bone metastasis with measurable tumor that swollen